InsiderClue
Stocks · Health care · Pharmaceutical Preparations

AEON Biopharma, Inc.

AEON Clue Score43
United States Fiscal year ends December CIK 0001837607
$0.25 -11.01% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.25 −97.49% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 12 Apr 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2021Operating income−1.9Net income8.2Fiscal year 2022Operating income−48.4Net income−52.6 −740.9%EPS, diluted−0.38Fiscal year 2024Operating income73.0Net income42.0EPS, diluted72.93Fiscal year 2025Operating income−12.8Net income−39.2 −193.4%EPS, diluted−3.95
FY2021FY2022FY2024FY2025
Operating income −1.9 −48.4 73.0 −12.8
Net income 8.2 −52.6 42.0 −39.2
Growth −740.9% −193.4%
EPS, diluted n/a −0.38 72.93 −3.95

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−1.5Fiscal year 2022Operating cash flow−35.6Capital expenditure−0.3Free cash flow−35.9Fiscal year 2024Operating cash flow−20.3Fiscal year 2025Operating cash flow−17.3Capital expenditure−0.0Free cash flow−17.3
FY2021FY2022FY2024FY2025
Operating cash flow −1.5 −35.6 −20.3 −17.3
Capital expenditure n/a −0.3 n/a −0.0
Free cash flow n/a −35.9 n/a −17.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash0.5Shareholders’ equity−16.9Fiscal year 2022Cash9.7Shareholders’ equity−287.5Fiscal year 2024Cash0.0Shareholders’ equity−28.6Fiscal year 2025Cash3.0Shareholders’ equity−55.0
FY2021FY2022FY2024FY2025
Cash 0.5 9.7 0.0 3.0
Shareholders’ equity −16.9 −287.5 −28.6 −55.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
n/a 34.8 14.2 4.1
n/a 13.7 13.6 12.2
−1.9 −48.4 73.0 −12.8
Growth −117.5%
8.2 −52.6 42.0 −39.2
n/a 0.0 0.0 0.0
8.2 −52.6 42.0 −39.2
Growth −740.9% −193.4%
Per share
n/a −0.38 77.74 −3.95
n/a −0.38 72.93 −3.95
Growth −105.4%
n/a 138.8 0.5 9.9
n/a 138.8 0.6 9.9
Growth −99.6% +1,622.7%

† The diluted share count jumps at 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 4 years on file.